IsoRay, Inc.  

(Public, NYSEMKT:ISR)   Watch this stock  
Find more results for NYSEAMEX:ISR
0.000 (0.00%)
Real-time:   4:02PM EDT
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.91 - 0.91
52 week 0.55 - 1.68
Open 0.91
Vol / Avg. 0.00/175,282.00
Mkt cap 51.77M
P/E     -
Div/yield     -
EPS -0.08
Shares 55.01M
Beta -0.87
Inst. own 8%
Sep 13, 2016
Q4 2016 IsoRay Inc Earnings Release (Estimated) Add to calendar
May 10, 2016
Q3 2016 IsoRay Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -99.72% -79.91%
Operating margin -110.70% -94.13%
EBITD margin - -81.07%
Return on average assets -23.65% -14.86%
Return on average equity -26.64% -16.50%
Employees 35 -
CDP Score - -


350 Hills St Ste 106
RICHLAND, WA 99354-5511
United States - Map
+1-509-3751202 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


IsoRay, Inc. develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in treatment for all solid tumors using Cesium-131. Cesium-131 is a radioactive isotope that can be produced by the neutron bombardment of Barium-130 (Ba-130). The Company's product candidate is Proxcelan Cesium-131. The Company markets the Proxcelan Cesium-131 brachytherapy seed for the treatment of prostate cancer; brain cancer; lung cancer; head and neck cancers; gynecological cancer: pelvic/abdominal cancer; colorectal cancer, and ocular melanoma. It also markets the GliaSite RTS for the treatment of brain cancer, such as primary and recurrent gliomas and metastic brain tumors. GliaSite RTS is a cleared balloon catheter device. The components included in the GliaSite RTS are the GliaSite Catheter Tray, GliaSite Access Tray, Iotrex Solidifier and either Iotrex or Cesitrex as the radiotherapy solution.

Officers and directors

Thomas C LaVoy Chairman of the Board, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Brien Ragle Chief Financial Officer
Age: 46
Bio & Compensation  - Reuters
William Cavanagh III Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Michael W. McCormick Director
Bio & Compensation  - Reuters
Philip J. Vitale M.D. Independent Director
Age: 68
Bio & Compensation  - Reuters